BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage

Table 2 The major characteristics of cohorts including BRAF^V600E and BRAF^non-V600E

Variables	*BRAF*^V600E (n = 27)		*BRAF*^non-V600E (n = 25)		Univariate analysis
Variables	Number	%	Number	%	Odds Ratio	95% Confidence Interval	P Value
Male	16	59.26	18	72.00	0.566	0.177–1.809	0.337
Diagnosis Age
Ages 20–35	9	33.33	6	24.00	1.583	0.469–5.350	0.459
Ages 36–50	9	33.33	8	32.00	1.062	0.333–3.390	0.918
Ages 51–80	7	25.93	11	44.00	0.445	0.139–1.433	0.175
Age 80+	2	7.41	0	0.00	1,615,474,843	0.000-	0.999
Cancer type detailed
Glioblastoma Multiform	20	74.07	14	56.00	2.245	0.698–7.219	0.175
Astrocytoma	3	11.11	6	24.00	0.396	0.087–1.794	0.229
Oligoastrocytoma	1	3.70	0	0.00	1,553,341,195	0.000-	1.000
Oligodendroglioma	0	0.00	3	12.00	0.000	0.000-	0.999
Gliosarcoma	0	0.00	2	8.00	0.000	0.000-	0.999
Other glioma	3	11.11	0	0.00	1,682,786,295	0.000-	0.999
Overall survival status
Deceased	14	51.85	11	44.00	1.371	0.460–4.087	0.572

ISSN: 1471-2377